XXII · Categories · M&A
XXII - Mergers and acquisitions
22nd Century Group Inc. (XXII) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for XXII
- 22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market PositionImmediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets BUFFALO, NY, Jan. 24, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the acquisition of privately held RX Pharmatech Ltd (RXP), a leading United Kingdom distributor of cannabinoids with 1,276 novel food applications with the U.K. Food Standards Agency (FSA). Terms of the agreement include an up-front paymen
- 22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis CompanyProvides Transformational Platform to Rapidly Grow Hemp/Cannabis FranchiseTransaction Immediately Accretive and Will Double Company's Total RevenueAdds Significant Commercial Scale to Existing Hemp/Cannabis FranchiseGVB Biopharma has Achieved Strong Growth and Leading Market Share in Hemp-Derived Active Ingredients BUFFALO, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization (CD